Title:
METHOD OF DELIVERY OF FUSOGENIC ONCOLYTIC VIRUS AND THERAPEUTIC MOLECULES
Document Type and Number:
WIPO Patent Application WO/2022/235905
Kind Code:
A3
Abstract:
Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides a method for treating cancer comprising administering to a subject in need thereof a checkpoint inhibitor in combination with a new generation regulatable fusogenic oncolytic herpes simplex virus-1 that is more effective at selective killing target cells, such as tumor cells. In various embodiments presented herein, the methods described herein is suitable for treatment of solid tumors, as well as other cancers.
Inventors:
YAO FENG (US)
Application Number:
PCT/US2022/027835
Publication Date:
December 08, 2022
Filing Date:
May 05, 2022
Export Citation:
Assignee:
BRIGHAM & WOMENS HOSPITAL INC (US)
International Classes:
C12N15/869; A61K35/763; A61K38/16; A61K39/395; A61K48/00; A61P35/00; C07K14/035; C07K16/28
Domestic Patent References:
| WO2020112471A1 | 2020-06-04 |
Foreign References:
| US20210085735A1 | 2021-03-25 |
Other References:
LEI QINGYANG, WANG DAN, SUN KAI, WANG LIPING, ZHANG YI: "Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors", FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, vol. 8, 21 July 2020 (2020-07-21), XP093012238, DOI: 10.3389/fcell.2020.00672
Attorney, Agent or Firm:
JODOIN, Jeanne Nicole et al. (US)
Download PDF: